Key Highlights

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached USD 80.00, up 3.22%, during the October 14, 2026 morning session. Partial-session volume was 682,035 shares, and no company announcement dated that day was found to account directly for the gain.
  • The company recorded USD 75.3 million of fiscal third-quarter 2026 revenue, compared with USD 27.8 million in the prior-year period. Its net loss was USD 194.3 million, or USD 1.36 per diluted share, according to its August 4, 2026 release.
  • In Phase 3, both SHASTA-3 and SHASTA-4 met their primary and secondary goals in severe hypertriglyceridemia. Median triglyceride levels fell 79% and 81%, respectively, and acute pancreatitis events were 78% lower than with placebo.
  • Cash, cash equivalents and securities amounted to USD 1.567 billion on June 30, 2026, versus USD 781.5 million on September 30, 2025. Arrowhead planned to file a supplemental application for severe hypertriglyceridemia by the end of 2026.

Recent Developments Behind the Move

No October 14 corporate announcement was identified, so the share gain appears to have occurred against a backdrop of recent clinical and launch progress. Arrowhead said quarterly U.S. REDEMPLO (plozasiran) prescriptions approximately doubled, more than 400 individual prescribers had written for the medicine, and major payers had adopted supportive coverage policies. The European Commission authorized the product for adults with familial chylomicronemia syndrome, and Australia had also approved it for that indication. Further SHASTA results were scheduled as a late-breaking presentation at the ESC Congress on August 30. A relative-strength reading near 32 points to recent share-price weakness, while the partial volume of 682,035 shares means the move from a single morning is not conclusive evidence of a durable change in sentiment.

Pipeline Milestones and Funding

Arrowhead obtained a Priority Review Voucher that could reduce the FDA's target review period for a severe hypertriglyceridemia application from the usual ten months to six months. The company expects to submit the plozasiran supplement by year-end 2026. Quarterly revenue of USD 75.3 million largely reflects collaboration and licensing payments, which can vary between periods. The net loss grew from USD 175.2 million to USD 194.3 million as research investment in RNA-interference programs continued. The Phase 3 YOSEMITE study of zodasiran for homozygous familial hypercholesterolemia is expected to finish in mid-2027. The voucher affects the agency review timetable only; it does not remove the time required to assemble and file a complete application.

Risks and Catalysts to Monitor

The key uncertainties are REDEMPLO's commercial adoption, regulatory review of a broader indication, and ongoing losses. A move into the larger severe-hypertriglyceridemia market could bring additional competitors and closer payer scrutiny. The USD 1.567 billion cash and securities balance is substantial compared with the quarterly loss, though additional capital raising could dilute shareholders if spending or cash needs increase. Arrowhead's fiscal year ends September 30, meaning its next results will cover fiscal Q4; the reporting date had not been announced at publication. Rival triglyceride-lowering treatments and established cardiovascular drugs could also affect prescribing once regulators consider the expanded indication. This is informational context, not investment advice.

What Investors Should Know

Arrowhead Pharmaceuticals was 3.22% higher at USD 80.00 on October 14, 2026, despite no identified announcement on the day. Recent support for the story includes approximately doubled REDEMPLO prescriptions, positive Phase 3 SHASTA findings and USD 1.567 billion in cash, equivalents and securities. Losses and the timing of regulatory action remain important counterweights. The next scheduled financial milestone is the fiscal fourth-quarter report, whose date was not yet public. This is not investment advice.